Paper · 40627530

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.

Gonzalez-Ericsson PI and 14 others. Clin Cancer Res, 2025. Cited by 10 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. Papers, record 40627530. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40627530

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.; PubMed
Journal: Clin Cancer Res; PubMed
Year: 2025; PubMed
Publication types: Clinical Trial, Phase I, Journal Article, Multicenter Study; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/40627530/; PubMed
DOI: https://doi.org/10.1158/1078-0432.ccr-24-3803; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12326521/; PubMed
The journal: https://conductscience.org/library/journal-index/9502500; PubMed
Citations, by iCite: 10; iCite
Relative citation ratio, by iCite: 2.41, provisional; iCite
Revised in PubMed: 2026-03-07; PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Gonzalez-Ericsson PI	Paula I	https://orcid.org/0000-0002-6292-6963
2	Unni N	Nisha	https://orcid.org/0000-0003-1549-4720
3	Jhaveri K	Komal	https://orcid.org/0000-0003-0472-1254
4	Stringer-Reasor E	Erica	https://orcid.org/0000-0002-1862-3367
5	Liu Q	Qi	https://orcid.org/0000-0001-8892-7078
6	Wang Y	Yu	https://orcid.org/0000-0002-2819-4551
7	Sanchez V	Violeta	https://orcid.org/0000-0001-6639-9024
8	Garcia G	Guadalupe	https://orcid.org/0009-0002-3073-7495
9	Sanders ME	Melinda E	https://orcid.org/0000-0001-7227-1764
10	Lehmann BD	Brian D	https://orcid.org/0000-0003-0407-5248

1 to 10 of 15Source PubMed

See all 15 authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Combined Chemotherapy Protocols	Major topic
Breast Neoplasms	Major topic
Adult
Aged
Female
Humans
Middle Aged
Fulvestrant
Maximum Tolerated Dose
Neoplasm Metastasis
Piperazines
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Quinoxalines
Erb-b2 Receptor Tyrosine Kinases
Receptors, Estrogen
Receptors, Fibroblast Growth Factor
Receptors, Progesterone
Tyrosine Kinase Inhibitors

Source PubMed

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
R01 CA273246	NCI NIH HHS	United States	R01CA273246	PubMed and NIH	NIH RePORTER
P30 CA013148	NCI NIH HHS	United States	P30CA013148	PubMed	NIH RePORTER
P30 CA068485	NCI NIH HHS	United States	P30CA068485	PubMed and NIH	NIH RePORTER
P30 CA008748	NCI NIH HHS	United States	P30CA008748	PubMed	NIH RePORTER
P50 CA098131	NCI NIH HHS	United States	P50CA098131	PubMed and NIH	NIH RePORTER
P30 CA142543	NCI NIH HHS	United States	P30CA142543	PubMed and NIH	NIH RePORTER
P50CA098131	Center for Cancer Research (CCR)		P50CA098131	PubMed and NIH	NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT03238196	Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	29,846,104	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.	Arch Pathol Lab Med	2018	https://conductscience.org/library/papers/29846104	PubMed
2	28,968,163	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.	J Clin Oncol	2017	https://conductscience.org/library/papers/28968163	PubMed
3	35,688,802	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.	Nat Commun	2022	https://conductscience.org/library/papers/35688802	PubMed
4	34,102,253	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.	Ann Oncol	2021	https://conductscience.org/library/papers/34102253	PubMed
5	30,914,635	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.	Nat Commun	2019	https://conductscience.org/library/papers/30914635	PubMed
6	38,603,651	Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.	JCO Precis Oncol	2024	https://conductscience.org/library/papers/38603651	PubMed
7	38,710,951	Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.	Nat Med	2024	https://conductscience.org/library/papers/38710951	PubMed
8	36,083,147	FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer.	Appl Immunohistochem Mol Morphol	2022	https://conductscience.org/library/papers/36083147	PubMed
9	20,473,330	Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.	Oncogene	2010	https://conductscience.org/library/papers/20473330	PubMed
10	26,947,331	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	Lancet Oncol	2016	https://conductscience.org/library/papers/26947331	PubMed

1 to 10 of 31

See all 31 references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMID	Title	Journal	Year	In Papers	Source
42,948,694	Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2- advanced breast cancer.	Acta Pharm Sin B	2026	https://conductscience.org/library/papers/42948694	PubMed
42,811,335	Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.	J Hematol Oncol	2026	https://conductscience.org/library/papers/42811335	PubMed
42,633,326	Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.	MedComm (2020)	2026	https://conductscience.org/library/papers/42633326	PubMed
42,351,448	Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies-A Narrative Review.	Diagnostics (Basel)	2026	https://conductscience.org/library/papers/42351448	PubMed
42,351,126	Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547.	J Transl Med	2026	https://conductscience.org/library/papers/42351126	PubMed
42,196,611	CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42196611	PubMed
42,083,272	Artesunate Induces G0/G1 Phase Arrest in Tumor Cells and Associates With Cyclin-Dependent Kinase 4 (CDK4).	Cancer Med	2026	https://conductscience.org/library/papers/42083272	PubMed
42,013,308	Covalent FAPI Imaging-Guided Precision Surgery in Patients with Medullary Thyroid Carcinoma: A Phase II Clinical Trial.	Clin Cancer Res	2026	https://conductscience.org/library/papers/42013308	PubMed
41,675,006	Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review.	Transl Breast Cancer Res	2026	https://conductscience.org/library/papers/41675006	PubMed
41,499,130	Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.	Cancer Res	2026	https://conductscience.org/library/papers/41499130	PubMed

1 to 10 of 11

See all 11 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
FULVESTRANT	CHEMBL1358	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL1358	ChEMBL
PALBOCICLIB	CHEMBL189963	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL189963	ChEMBL
ERDAFITINIB	CHEMBL3545376	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3545376	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40627530

GET https://conductscience.org/api/papers/v1/40627530/references?page=2

API reference For AI assistants